American Heart Journal
Volume 151, Issue 5 , Pages 976.e1-976.e6 , May 2006

Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: Analysis of the Orbofiban in Patients with Unstable coronary Syndromes–Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial

  • Shaul Atar, MD

      Affiliations

    • Division of Cardiology, University of Texas Medical Branch, Galveston, TX
    • ,
  • Christopher P. Cannon, MD, FACC

      Affiliations

    • Division of Cardiology, Brigham and Women's Hospital, Boston, MA
    • ,
  • Sabina A. Murphy, MPH

      Affiliations

    • Division of Cardiology, Brigham and Women's Hospital, Boston, MA
    • ,
  • Salvatore Rosanio, MD,PhD

      Affiliations

    • Division of Cardiology, University of Texas Medical Branch, Galveston, TX
    • ,
  • Barry F. Uretsky, MD, FACC

      Affiliations

    • Division of Cardiology, University of Texas Medical Branch, Galveston, TX
    • ,
  • Yochai Birnbaum, MD, FACC

      Affiliations

    • Division of Cardiology, University of Texas Medical Branch, Galveston, TX
    • Corresponding Author InformationReprints requests: Yochai Birnbaum, MD, The Division of Cardiology, The University of Texas Medical Branch, 5.106 John Sealy Annex, 301 University Blvd., Galveston, TX 77555-0553.

Received 27 September 2005 ,Accepted 7 February 2006.

References 

  1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423
  2. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–2346
  3. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(Suppl 1):III39–III43
  4. Wainwright CL. Statins—is there no end to their usefulness?. Cardiovasc Res. 2005;65:296–298
  5. Undas A, Celinska-Lowenhoff M, Kaczor M, et al. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost. 2004;91:1065–1077
  6. Birnbaum Y, Ye Y, Rosanio S, et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res. 2005;65:345–355
  7. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149–156
  8. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1815–1823
  9. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005;25:287–294
  10. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation. 2004;109(Suppl 1):II18–II26
  11. Chen JC, Huang KC, Wingerd B, et al. HMG-CoA reductase inhibitors induce COX-2 gene expression in murine macrophages: role of MAPK cascades and promoter elements for CREB and C/EBPbeta. Exp Cell Res. 2004;301:305–319
  12. Russell RI. Protective effects of the prostaglandins on the gastric mucosa. Am J Med. 1986;81:2–4

PII: S0002-8703(06)00128-1

doi: 10.1016/j.ahj.2006.02.013

American Heart Journal
Volume 151, Issue 5 , Pages 976.e1-976.e6 , May 2006

Article Tools

* Image Usage & Resolution